Cellectar Biosciences, INC S-1 registration statements

Cellectar Biosciences has filed an amendment to its registration statement to facilitate the resale of up to 51,998,413 shares of common stock by selling stockholders.

Cellectar Biosciences, Inc. has filed a Form S-1 registration statement to allow selling stockholders to resell up to 51,206,051 shares of common stock.

Cellectar Biosciences, Inc. filed an S-1 registration statement for the resale of up to 2,096,188 shares of common stock by selling stockholders, following a recent warrant inducement transaction that generated $5.8 million in gross proceeds.

Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has filed an S-1/A registration statement for a public offering of up to 755,667 Class A or Class B Units to raise approximately $5.0 million, primarily to advance its cancer drug pipeline, despite facing significant financial constraints and a recent reverse stock split.

Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has filed an S-1 registration statement for a public offering of up to 755,667 Class A or Class B Units to raise approximately $5.0 million, while acknowledging that these proceeds will not be sufficient to fund a key clinical trial through data readout and raising substantial doubt about its ability to continue as a going concern.

Cellectar Biosciences is registering for resale up to 19,221,348 shares of its common stock by selling stockholders after a warrant inducement transaction.